Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk

Dow Jones

10/28

2337 GMT - Investors are expected to view CSL's decision to delay a spinoff of flu-vaccine unit Seqirus positively, says RBC Capital Markets analyst Craig Wong-Pan. With U.S. flu-vaccine rates in decline, he says most investors didn't expect the spinoff to create value. Still, Wong-Pan says he expects CSL shares to underperform the market Tuesday given the company's announcement that it is cutting guidance, though he says the tempered growth outlook is "somewhat understandable given it has been mostly attributable to weakness in the influenza vaccine market." CSL shares are down some 15% to about A$180/share. (mike.cherney@wsj.com)

(END) Dow Jones Newswires

October 27, 2025 19:37 ET (23:37 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2578706606"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578706606\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578706606?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 07:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578706606","market":"us","top_or_hot":-1,"title":"Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2337 GMT - Investors are expected to view CSL's decision to delay a spinoff of flu-vaccine unit Seqirus positively, says RBC Capital Markets analyst Craig Wong-Pan. With U.S. flu-vaccine rates in decline, he says most investors didn't expect the spinoff to create value. Still, Wong-Pan says he expects CSL shares to underperform the market Tuesday given the company's announcement that it is cutting guidance, though he says the tempered growth outlook is \"somewhat understandable given it has been mostly attributable to weakness in the influenza vaccine market.\" CSL shares are down some 15% to about A$180/share. (mike.cherney@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 27, 2025 19:37 ET (23:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvestors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-10-28 07:37</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2337 GMT - Investors are expected to view CSL's decision to delay a spinoff of flu-vaccine unit Seqirus positively, says RBC Capital Markets analyst Craig Wong-Pan. With U.S. flu-vaccine rates in decline, he says most investors didn't expect the spinoff to create value. Still, Wong-Pan says he expects CSL shares to underperform the market Tuesday given the company's announcement that it is cutting guidance, though he says the tempered growth outlook is \"somewhat understandable given it has been mostly attributable to weakness in the influenza vaccine market.\" CSL shares are down some 15% to about A$180/share. (mike.cherney@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 27, 2025 19:37 ET (23:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL.AU","symbol_name":"CSL LIMITED","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2578706606","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578706606","pubTimestamp":1761608220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2337 GMT - Investors are expected to view CSL's decision to delay a spinoff of flu-vaccine unit Seqirus positively, says RBC Capital Markets analyst Craig Wong-Pan. With U.S. flu-vaccine rates in decline, he says most investors didn't expect the spinoff to create value. Still, Wong-Pan says he expects CSL shares to underperform the market Tuesday given the company's announcement that it is cutting guidance, though he says the tempered growth outlook is \"somewhat understandable given it has been mostly attributable to weakness in the influenza vaccine market.\" CSL shares are down some 15% to about A$180/share. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CSL.AU":"CSL LIMITED","BK7501":"新冠治疗股","BK4086":"建筑产品","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","CSL":"卡莱尔伙伴","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK7508":"医药生物股","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK7511":"ESG概念","BK7067":"生物科技","ISBC":"投资者银行","BK4211":"区域性银行"},"translate_title":"投资者可能会为CSL推迟Seqirus分拆的决定欢呼——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":0.9,"CSL":1.5,"ISBC":1.5},"content_text":"2337 GMT - Investors are expected to view CSL's decision to delay a spinoff of flu-vaccine unit Seqirus positively, says RBC Capital Markets analyst Craig Wong-Pan. With U.S. flu-vaccine rates in decline, he says most investors didn't expect the spinoff to create value. Still, Wong-Pan says he expects CSL shares to underperform the market Tuesday given the company's announcement that it is cutting guidance, though he says the tempered growth outlook is \"somewhat understandable given it has been mostly attributable to weakness in the influenza vaccine market.\" CSL shares are down some 15% to about A$180/share. (mike.cherney@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 27, 2025 19:37 ET (23:37 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}